CIMG Acquires Daren Business Technology Limited
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy IMG?
Source: PRnewswire
- Acquisition Agreement: CIMG's wholly-owned subsidiary DZR signed a share purchase agreement on February 5, 2026, to acquire 100% of Daren for approximately $40 million in shares, with closing expected within 30 days, marking a strategic expansion into the biopharmaceutical sector.
- Phased Payment Structure: The purchase consideration will be released in four phases—6%, 14%, 28%, and 52%—based on Daren's performance targets over a 3.5-year period, ensuring ongoing performance incentives for Daren and alignment with CIMG's growth objectives.
- Performance Targets Set: Daren must achieve increasing audited revenue targets from $29 million to $257 million between April 2026 and September 2029, which will enhance its competitiveness in the biopharmaceutical market while providing CIMG with a stable revenue stream.
- Strategic Diversification: CIMG's CEO Alice Wang stated that this acquisition is a key step in the company's diversification strategy, with plans to increase investments in the biopharmaceutical field, leveraging technological integration and innovative models to drive new growth engines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMG
About IMG
CIMG Inc., formerly NuZee, Inc., is a digital marketing, sales and distribution company for various consumer products with focuses on food and beverages. The Company focuses on specialty coffee and technologies. The Company's products include single serve pour over, coffee brew bag coffee products, and single serve coffee format, DRIPKIT pour over products. Its DRIPKIT pour over format features a large-size single serve pour over pack that sits on top of the cup and delivers to its customers in the United States, Canada and Mexico. The Company also sells single serve coffee products, including its flagship Coffee Blenders line of both single serves pour over coffee and coffee brew bag coffee products. Coffee Blenders also offers Coldpresso latte product line that is available to purchase in Korea and online. The Company sells its Twin Peaks single serve pour over coffee exclusively via Amazon. It has a sales and distribution network for maca infused food and beverages.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Strategic Partnership MOU: CIMG has signed a memorandum of understanding with iZUMi to explore broader cooperation in digital asset infrastructure and on-chain liquidity services, indicating a strong intent for future collaboration.
- Potential Asset Acquisition: Under the MOU, CIMG may acquire certain assets, patents, and technologies from iZUMi, which could enhance CIMG's capabilities in managing its digital assets, particularly its Bitcoin holdings.
- Digital Asset Strategy: CIMG aims to evaluate new ways to manage and utilize its digital assets through this partnership, further driving growth in its digital health and sales development sectors.
- Client Portfolio Expansion: CIMG's client portfolio includes brands like Kangduoyuan and Maca-Noni, and this collaboration is expected to enhance its commercial value and market competitiveness by integrating iZUMi's services and IZI tokens.
See More
- Strategic Partnership MOU: CIMG has signed a memorandum of understanding with iZUMi Finance to explore extensive cooperation in digital asset infrastructure and on-chain liquidity services, indicating a strong intent for future collaboration between the parties.
- Potential Asset Acquisition: Under the MOU, CIMG may acquire certain assets, patents, and technologies from iZUMi, which would enhance CIMG's competitiveness in the digital health and sales development sectors.
- Digital Asset Management: CIMG intends to evaluate ways to manage and utilize its digital assets, including Bitcoin holdings, through this partnership, thereby increasing its commercial value and market position.
- Client Portfolio Expansion: CIMG focuses on leveraging AI and cryptocurrencies to drive business growth, with existing clients including several well-known brands, and future collaborations are expected to further expand its client base and market influence.
See More
- Significant Revenue Growth: CIMG achieved substantial revenue growth in FY 2025, driven by optimizing its business structure and focusing on two core sectors: AI computing infrastructure and digital health, demonstrating the effectiveness of the company's strategic transformation.
- Continued Reduction in Net Loss: The company reported a continued reduction in net loss during the reporting period, reflecting positive outcomes from the launch of new businesses and the progress of major contracts, alongside refined management practices.
- Digital Asset Strategy: CIMG plans to increase its Bitcoin holdings based on market conditions to strengthen corporate assets and core competitiveness, aiming to create sustainable value for shareholders, customers, and partners.
- Diverse Client Portfolio: The company's current client portfolio includes various brands such as Kangduoyuan, Maca-Noni, Qianmao, Huomao, and Coco-mango, showcasing its broad influence in the digital health and sales development sectors.
See More
- Significant Revenue Growth: CIMG reported approximately $10.3 million in revenue for FY 2025, reflecting a remarkable year-on-year increase of 433%, primarily driven by new computing power service contracts and its digital health business, indicating strong market performance.
- Substantial Reduction in Net Loss: The company's net loss decreased by approximately 45.5% year-on-year, showcasing the effectiveness of its business transformation and cost optimization efforts, which highlight significant progress in operational efficiency.
- Increased Digital Asset Reserves: As of September 30, 2025, CIMG held around 500 Bitcoins valued at approximately $57.05 million, contributing to a staggering 1,227% year-on-year increase in total assets, demonstrating the success of its digital asset strategy.
- Enhanced Shareholder Value: With a book value per share of approximately $2.99, combined with the company's strategic focus on AI computing infrastructure and digital health, it is expected to create sustainable value for shareholders, customers, and partners.
See More
- Acquisition Agreement: CIMG's wholly-owned subsidiary DZR signed a share purchase agreement on February 5, 2026, to acquire 100% of Daren for approximately $40 million in shares, with closing expected within 30 days, marking a strategic expansion into the biopharmaceutical sector.
- Phased Payment Structure: The purchase consideration will be released in four phases—6%, 14%, 28%, and 52%—based on Daren's performance targets over a 3.5-year period, ensuring ongoing performance incentives for Daren and alignment with CIMG's growth objectives.
- Performance Targets Set: Daren must achieve increasing audited revenue targets from $29 million to $257 million between April 2026 and September 2029, which will enhance its competitiveness in the biopharmaceutical market while providing CIMG with a stable revenue stream.
- Strategic Diversification: CIMG's CEO Alice Wang stated that this acquisition is a key step in the company's diversification strategy, with plans to increase investments in the biopharmaceutical field, leveraging technological integration and innovative models to drive new growth engines.
See More
- Acquisition Agreement: CIMG's wholly-owned subsidiary DZR signed a share purchase agreement on February 5, 2026, to acquire 100% of Daren's equity for approximately $40 million in stock, with the transaction expected to close within 30 days, marking a strategic expansion into the biopharmaceutical sector.
- Phased Payment Structure: The purchase consideration will be released in four phases—6%, 14%, 28%, and 52%—based on Daren's performance targets over a 3.5-year period, ensuring CIMG maintains ongoing oversight and incentives tied to Daren's performance.
- Performance Targets Set: Daren must achieve increasing audited revenue targets of $29 million, $71 million, $143 million, and $257 million from April 2026 to September 2029, reflecting CIMG's confidence in Daren's growth potential and providing a clear path for revenue growth.
- Strategic Diversification: CIMG's Chairwoman and CEO Alice Wang stated that this acquisition is a key step in the company's diversification strategy, with plans to increase investments in the biopharmaceutical field, leveraging technological integration and model innovation to build a new growth engine and enhance market competitiveness.
See More





